Coronary vasospasm: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 111: Line 111:
*Repeat prolonged PTCA for 2-5 minutes at low pressures (1-4 atmospheres).
*Repeat prolonged PTCA for 2-5 minutes at low pressures (1-4 atmospheres).
*Stenting should be a last ditch option, and used if above measures have failed, as it may lead to propagation of spasm to a new location.  Refractory vasospasm may be indicative of dissection, which is also an indication for stenting.
*Stenting should be a last ditch option, and used if above measures have failed, as it may lead to propagation of spasm to a new location.  Refractory vasospasm may be indicative of dissection, which is also an indication for stenting.


===Chronic Vasospasm===
===Chronic Vasospasm===
Therapeutic treatment of chronic vasospasm should be performed in this order (step-wise fashion):
Therapeutic treatment of chronic vasospasm should be performed in this order (step-wise fashion):


====Medical Therapy====
=====Medical Therapy=====
*Risk factor modification (smoking cessation, lipid control) is recommended for all patients.
*Risk factor modification (smoking cessation, lipid control) is recommended for all patients.
*Begin pharmacologic therapy with oral calcium channel blockers (diltiazem, verapamil, nifedipine) and/or nitrates.  If monotherapy is ineffective, begin combination therapy which is generally well tolerated (10% of patients may require 2 calcium channel blockers). If refractory or multi-vessel spasm is present, multiple CCBs are likely necessary, as these patients are at high risk for ventricular arrhythmias. Alpha blockers may also be useful if there is incomplete response to CCB and nitrates.  
*Begin pharmacologic therapy with oral calcium channel blockers (diltiazem, verapamil, nifedipine) and/or nitrates.  If monotherapy is ineffective, begin combination therapy which is generally well tolerated (10% of patients may require 2 calcium channel blockers). If refractory or multi-vessel spasm is present, multiple CCBs are likely necessary, as these patients are at high risk for ventricular arrhythmias. Alpha blockers may also be useful if there is incomplete response to CCB and nitrates.  
Line 122: Line 121:
*Certain medications should be avoided: nonselective beta blockers, aspirin, and sumatriptan can exacerbate vasospasm. Hormone replacement therapy (estrogen-progestin) have been associated with an increase in cardiac events (HERS-II and WHI trials) and should also be avoided.  
*Certain medications should be avoided: nonselective beta blockers, aspirin, and sumatriptan can exacerbate vasospasm. Hormone replacement therapy (estrogen-progestin) have been associated with an increase in cardiac events (HERS-II and WHI trials) and should also be avoided.  


====Percutaneous Intervention (PCI)====
=====Percutaneous Intervention (PCI)=====
*If vasospasm has a clearly definable area that is associated with coronary artery disease and refractory to medical therapy, stenting may be an effective strategy. However, stenting may simply propagate the spasm to a proximal or distal location in the vessel.
*If vasospasm has a clearly definable area that is associated with coronary artery disease and refractory to medical therapy, stenting may be an effective strategy. However, stenting may simply propagate the spasm to a proximal or distal location in the vessel.
*Following any PCI, adjunctive medical therapy must be continued.
*Following any PCI, adjunctive medical therapy must be continued.
Line 129: Line 128:
*The role of revascularization in the setting of multivessel vasospasm is uncertain.
*The role of revascularization in the setting of multivessel vasospasm is uncertain.


====Surgery====
=====Surgery=====
*In the rare circumstance that a patient is refractory to pharmacologic and percutaneous therapy, surgical denervation and plexectomy have been effective.
*In the rare circumstance that a patient is refractory to pharmacologic and percutaneous therapy, surgical denervation and plexectomy have been effective.


==How To Know if Treatment of PCI-Induced Vasospam is Working==
==How To Know if Treatment of PCI-Induced Vasospam is Working==

Revision as of 18:30, 22 June 2010

Coronary vasospasm
ICD-9 413.1
DiseasesDB 13727
MedlinePlus 000159
eMedicine med/447 
MeSH D003329

WikiDoc Resources for Coronary vasospasm

Articles

Most recent articles on Coronary vasospasm

Most cited articles on Coronary vasospasm

Review articles on Coronary vasospasm

Articles on Coronary vasospasm in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Coronary vasospasm

Images of Coronary vasospasm

Photos of Coronary vasospasm

Podcasts & MP3s on Coronary vasospasm

Videos on Coronary vasospasm

Evidence Based Medicine

Cochrane Collaboration on Coronary vasospasm

Bandolier on Coronary vasospasm

TRIP on Coronary vasospasm

Clinical Trials

Ongoing Trials on Coronary vasospasm at Clinical Trials.gov

Trial results on Coronary vasospasm

Clinical Trials on Coronary vasospasm at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Coronary vasospasm

NICE Guidance on Coronary vasospasm

NHS PRODIGY Guidance

FDA on Coronary vasospasm

CDC on Coronary vasospasm

Books

Books on Coronary vasospasm

News

Coronary vasospasm in the news

Be alerted to news on Coronary vasospasm

News trends on Coronary vasospasm

Commentary

Blogs on Coronary vasospasm

Definitions

Definitions of Coronary vasospasm

Patient Resources / Community

Patient resources on Coronary vasospasm

Discussion groups on Coronary vasospasm

Patient Handouts on Coronary vasospasm

Directions to Hospitals Treating Coronary vasospasm

Risk calculators and risk factors for Coronary vasospasm

Healthcare Provider Resources

Symptoms of Coronary vasospasm

Causes & Risk Factors for Coronary vasospasm

Diagnostic studies for Coronary vasospasm

Treatment of Coronary vasospasm

Continuing Medical Education (CME)

CME Programs on Coronary vasospasm

International

Coronary vasospasm en Espanol

Coronary vasospasm en Francais

Business

Coronary vasospasm in the Marketplace

Patents on Coronary vasospasm

Experimental / Informatics

List of terms related to Coronary vasospasm

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Associate Editors-in-Chief: Alexander Morss, M.D.; Brian Bigelow, M.D.; David Lorenz, M.D.; Jason Choi, M.D.; Felipe Chaparro M.D.; David M. Leder, M.D.

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Synonyms and related key words: Coronary vasoconstriction, coronary artery spasm, vasospastic angina, variant angina, Prinzmetal angina, Prinzmetal's angina, focal coronary artery vasospasm, dynamic coronary obstruction

Overview

Coronary vasospasm is a multi-factorial, transient, and abrupt reduction of luminal diameter of an epicardial coronary artery due to inappropriate constriction of coronary smooth muscle that can generate distal ischemia. This may occur spontaneously or in the context of angioplasty, particularly if denudation of the endothelium or dissection occurs. Also, the vasospasm can either be focal or multifocal (which compromises more than one vessel).

Subtypes of Vasospasm

A subtype of epicardial coronary artery spasm is known as Prinzmetal's angina. In this subtype of epicardial coronary artery vasospasm, symptoms typically occur at rest, rather than on exertion (thus attacks usually occur at night). Two-thirds of patients have concurrent atherosclerosis of a major coronary artery, but this is often mild or not in proportion to the degree of symptoms. Prinzmetal's angina is typically associated with specific EKG changes (elevation rather than depression of the ST segment).

(Cardiac) syndrome X is angina (chest pain) with signs associated with decreased blood flow to heart tissue but with normal coronary arteries. It is thought to involve the coronary microvasculature rather than the large epicardial arteries. It occurs more often in young women. Some studies have found increased risk of other vasospastic disorders in syndrome X patients, such as migraine and Raynaud's phenomenon. It is treated with calcium channel blockers, such as nifedipine, and usually carries a favorable prognosis. This is a distinct diagnosis from Prinzmetal's angina which involves spasm of the main epicardial coronary arteries. Syndrome X involves spasm of the downstream microvasculature.

Coronary vasospasm can occur in either a single epicardial coronary artery or in multiple epicardial coronary arteryies. [1][2] When it does occur in multiple vessels, the prognosis is worse as it may result in ventricular tachycardia or ventricular fibrillation. The patient with multivessel spasm may benefit from dual calcium channel blockade.

Pathophysiology

The exact pathogenesis of coronary vasospasm is not well understood, but some causes and contributing factors are known. Sometimes coronary vasospasm is induced by angioplasty (PCI-induced), which occurs secondary to endothelial denudation and nitric oxide loss. Others are catheter-induced, which is caused by a contact of a catheter without balloon deployment. Catheter-induced coronary vasospasms are usually short-lived. They are most prone to occur at the ostium of the right coronary artery (RCA), and the left main is less susceptible to ostial spasm. Additionally, the autonomic nervous system and endothelial dysfunction can lead to chronic intermittent vasospasm, which usually occurs where a fixed, noncalcified stenosis is located.

Epidemiology

Young patients with fewer cardiovascular risk factors (with the exception of smoking) are at a higher risk for coronary vasospasm, as are noncalcified lesions and eccentric plaques. Also, rotoblator cases are more prone to coronary vasospasm, with a 4-36% incidence.

Diagnosis

Physicians should suspect vasospasm if ST segment elevation is detected in patients experiencing angina, and if the ECG completely returns to baseline upon resolution of symptoms. Once detected, aggressive management of coronary vasospasm is necessary, as vasospasm can provoke fatal arrhythmias or myocardial infarction. The definitive diagnosis of coronary vasospasm is made angiographically by demonstration of reduction of luminal diameter in a discrete segment of the vessel, which is proven to be reversible. Reversibility may be demonstrated by previous or subsequent enlargement of luminal diameter, often after the administration of intracoronary vasodilators. The differential diagnosis of coronary spasm during percutaneous coronary intervention includes abrupt closure due to dissection or thrombus formation.


Differential Diagnosis of Underlying Causes of Coronary Vasospasm

(In alphabetical order)

Treatment

The main goals of treating coronary vasospasm are to reverse the spontaneous, abrupt luminal diameter reduction, reverse PTCA-induced vasospasm, and to stabilize chronic intermittent vasospasm.

Calcium channel blockers and nitrates are the mainstay of chronic therapy for coronary vasospasm. Atropine has also been used to treat the condition.[3]

Treatment of PCI-Induced Vasospasm

  • Intracoronary vasodilators should be given slowly through guiding catheters with side holes to maximize the delivery into the artery with minimal dispersal through the catheter side holes.
    • Intracoronary nitroglycerin 100-300 mcg. Generally well tolerated and have an additive effect.
    • Intracoronary calcium channel blockers. Generally well tolerated, have an additive effect, and have a small risk of transient heart block.
      • Diltiazem 0.5-2.5 mg/min, up to 5-10mg
      • Verapamil 100 mcg/min, up to 1.0-1.5 mg
      • Nicardipine 100-300 mcg
      • Nifedipine 10 mg sublingual (SL)
    • Intracoronary nitroprusside 100-300 mcg
  • Systemic vasodilators
    • Nifedipine 10mg sublingual
    • Atropine 0.5mg IV. Particularly useful in the setting of hypotension or bradycardia.
  • Device related treatments
    • Removal of interventional hardware with guide wire in place to minimize mechanical provocation. This strategy may minimize distal vessel spasm.
    • Repeat prolonged (2-5 min) PTCA at low pressure (1-4 atmospheres). May mechanically "break" vasospasm.
    • Stenting. May improve focal spasm, but may simply propagate the site of spasm to a location proximal or distal to the stent within the vessel, so it should be avoided if possible.

Treatments for chronic vasospasm

  • Calcium channel blockers. Well tolerated and can aid with hypertension control. A combination of dihyropyridine and non-dihydropyridine calcium channel blockers should be used in patients with refractory coronary vasospasm, particularly if it has resulted in ventricular arrhythmia. Multiple calcium channel blockers may be required in patients with refractory or multivessel spasm. A patient who has suffered VT/VF due to spontaneous vasospasm (not due to acute infarction) should also likely undergo ICD placement.
    • Diltiazem 240-360mg PO qd
    • Verapamil 240-480mg PO qd
    • Nifedipine XL 60-120mg PO qd
    • Nicardipine 40-160mg PO qd
  • Long-acting nitrates Well tolerated and can aid with hypertension control.
    • Isosorbide mononitrate (Imdur) 60-240mg PO qd
    • Isosorbide dinitrate (Isordil) 20-40mg PO tid
  • Statins May improve endothelial dysfunction and lower inflammation. A small, randomized control trial showed that fluvastatin 30mg daily reduced rates of vasospasm. Statins also provide benefits of LDL lowering and plaque stabilization.
    • Fluvastatin 30mg PO qd
  • Hormone replacement therapy. This remains controversial, particularly due to the risk of concern of increased cardiac events.
  • Smoking cessation should be emphasized in all patients, as it contains non-cardiac benefits as well. It lowers future event rates of vasospasm and acute coronary syndromes.
  • PTCA/stenting While resolution occurs following PTCA/stenting in some cases, spasm can propagate to a new location, proximal or distal to the stented site.
  • ICD placement as described above for patients with VT/VF due to spontaneous coronary vasospasm without other provocation that may be treated.
  • Surgical autonomic denervation/plexectomy Can be useful in cases that are refractory to medical therapy or percutaneous intervention. It's reserved only for the most refractory cases.

Making a Selection

PCI-Induced Vasospasm

Therapeutic treatment of PCI-induced vasospasm should be performed in this order (step-wise fashion):

  • Initial step is intracoronary vasodilatation with IC calcium channel blockers and/or nitrates, which should be given slowly if using guiding catheters with side holes to avoid dispersal of the drug through the holes instead of into the coronary artery.
  • If one agent is unsuccessful, combined therapy should be implemented as these medications have an additive effect. Be mindful for heart block with CCB therapy.
  • IV Atropine can be useful if there is associated hypotension of bradycardia.
  • Should medical therapy fail, remove all hardware and leave the guidewire in place to maintain position. This may minimize distal vessel spasm.
  • Repeat prolonged PTCA for 2-5 minutes at low pressures (1-4 atmospheres).
  • Stenting should be a last ditch option, and used if above measures have failed, as it may lead to propagation of spasm to a new location. Refractory vasospasm may be indicative of dissection, which is also an indication for stenting.

Chronic Vasospasm

Therapeutic treatment of chronic vasospasm should be performed in this order (step-wise fashion):

Medical Therapy
  • Risk factor modification (smoking cessation, lipid control) is recommended for all patients.
  • Begin pharmacologic therapy with oral calcium channel blockers (diltiazem, verapamil, nifedipine) and/or nitrates. If monotherapy is ineffective, begin combination therapy which is generally well tolerated (10% of patients may require 2 calcium channel blockers). If refractory or multi-vessel spasm is present, multiple CCBs are likely necessary, as these patients are at high risk for ventricular arrhythmias. Alpha blockers may also be useful if there is incomplete response to CCB and nitrates.
  • Due to their ability to improve endothelial function, statins should be considered for vasospasm.
  • Certain medications should be avoided: nonselective beta blockers, aspirin, and sumatriptan can exacerbate vasospasm. Hormone replacement therapy (estrogen-progestin) have been associated with an increase in cardiac events (HERS-II and WHI trials) and should also be avoided.
Percutaneous Intervention (PCI)
  • If vasospasm has a clearly definable area that is associated with coronary artery disease and refractory to medical therapy, stenting may be an effective strategy. However, stenting may simply propagate the spasm to a proximal or distal location in the vessel.
  • Following any PCI, adjunctive medical therapy must be continued.
  • Resolution of symptoms, ECG changes, and angiographic vasospasm is usually apparent within 1 minute post-procedure.
  • Refractory spasm occurring during PCI is likely secondary to dissection, which requires stenting unless the artery is small and the patient is clinically stable.
  • The role of revascularization in the setting of multivessel vasospasm is uncertain.
Surgery
  • In the rare circumstance that a patient is refractory to pharmacologic and percutaneous therapy, surgical denervation and plexectomy have been effective.

How To Know if Treatment of PCI-Induced Vasospam is Working

Therapies for vasospasm will usually take effect within seconds to one minute.

  • Repeat angiography
  • Resolution of ECG changes (ST depression or elevation)
  • Resolution of symptoms, if present

Pathological Findings

Images courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology

References

  1. Ahooja V, Thatai D (2007). "Multivessel coronary vasospasm mimicking triple-vessel obstructive coronary artery disease". J Invasive Cardiol. 19 (7): E178–81. PMID 17620681. Unknown parameter |month= ignored (help)
  2. Miwa K, Ishii K, Makita T, Okuda N (2004). "Diagnosis of multivessel coronary vasospasm by detecting postischemic regional left ventricular delayed relaxation on echocardiography using color kinesis". Circ. J. 68 (5): 483–7. PMID 15118293. Unknown parameter |month= ignored (help)
  3. Turkoglu S, Arpag U, Timurkaynak T (2007). "Spontaneous coronary vasospasm in the catheterisation laboratory: prompt resolution after atropine injection". Heart. 93 (2): 215. doi:10.1136/hrt.2006.093187. PMID 17228071. Unknown parameter |month= ignored (help)

Further reading

Template:Heart diseases Template:SIB

Template:WH Template:WS